SynKIR-110 is under clinical development by Verismo Therapeutics and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData, Phase I drugs for Malignant Pleural Mesothelioma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SynKIR-110’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SynKIR-110 overview

SynKIR-110 is under development for the treatment of cholangiocarcinoma, ovarian cancer, malignant pleural mesothelioma, peritoneal cancer and fallopian tube cancer. The drug candidate comprises of T cells genetically modified to express killer immunoglobulin-like receptors (KIRs) and DAP12 protein that deliver important signals to T cells that promote T cell proliferation. It acts by targeting cells expressing mesothelin. It is administered through intravenous drip route. The drug candidate is being developed based on KIR-CAR platform. It was under development for the treatment of pancreatic cancer.

Verismo Therapeutics overview

Verismo Therapeutics, Inc., is a pharmaceutical company develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. The company is headquartered United States.

For a complete picture of SynKIR-110’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.